Arrowhead Pharmaceuticals Inc is a pioneering biopharmaceutical company focused on developing innovative medicines for challenging diseases. With a robust pipeline, it targets conditions like hypertriglyceridemia, non-alcoholic steatohepatitis, and various pulmonary diseases, among others. Arrowhead is actively conducting clinical trials across different phases to combat diseases such as chronic hepatitis B, liver diseases, and alpha-1 antitrypsin deficiency-related liver disease. The company collaborates with industry giants like Janssen Pharmaceuticals and Amgen, showcasing its commitment to advancing healthcare. Founded in 2003 and based in Pasadena, California, Arrowhead is at the forefront of medical research.
Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and…
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the…
Sarepta Therapeutics (NASDAQ:SRPT | SRPT Price Prediction) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Monday's top analyst upgrades and downgrades included CyberArk Software, Diageo, Dish Network, Electronic Arts, Fox, Gilead Sciences, Molson Coors Beverage, O’Reilly Automotive, PacWest Bancorp, Palo Alto Networks, SoFi Technologies and Twilio.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Wednesday's top analyst upgrades and downgrades included APA, Delta Air Lines, Generac, Lululemon Athletica, Microchip Technology, Paccar, Philip Morris International, Pinduoduo, Shopify, Taboola.com and Welltower.
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor, Playtika, Peloton Interactive, Unity Software, Walmart and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including American Water Works, Carnival, Duke Energy, Okta and Zscaler.
The Friday afternoon analyst calls were focused on Biogen, Fortinet, Pinterest, Snap and more.
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.Â
Chris Lange 
